NO982006L - Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden - Google Patents

Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden

Info

Publication number
NO982006L
NO982006L NO982006A NO982006A NO982006L NO 982006 L NO982006 L NO 982006L NO 982006 A NO982006 A NO 982006A NO 982006 A NO982006 A NO 982006A NO 982006 L NO982006 L NO 982006L
Authority
NO
Norway
Prior art keywords
skin
active substances
transdermal delivery
therapeutic preparation
transdermal
Prior art date
Application number
NO982006A
Other languages
English (en)
Other versions
NO982006D0 (no
Inventor
Bodo Asmussen
Andreas Koch
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO982006D0 publication Critical patent/NO982006D0/no
Publication of NO982006L publication Critical patent/NO982006L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet et terapeutisk preparat for transdermal tilførsel av virksomme stoffer gjennom huden, inneholdende tilsatser som bevirker en økning av den perkutane absorpsjonsraten av transdermalt, normalt bare utilstrekkelig resorberbare virkestoffer, kjennetegnet ved at tilsatsene er HMG-CoA-reduktase-inhibitorer.
NO982006A 1995-11-06 1998-05-04 Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden NO982006L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541260A DE19541260A1 (de) 1995-11-06 1995-11-06 Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
PCT/EP1996/004138 WO1997017061A1 (de) 1995-11-06 1996-09-21 Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut

Publications (2)

Publication Number Publication Date
NO982006D0 NO982006D0 (no) 1998-05-04
NO982006L true NO982006L (no) 1998-05-04

Family

ID=7776710

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982006A NO982006L (no) 1995-11-06 1998-05-04 Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden

Country Status (21)

Country Link
US (1) US6379696B1 (no)
EP (1) EP0859595B1 (no)
JP (1) JP2001507331A (no)
KR (1) KR100445940B1 (no)
CN (1) CN1201385A (no)
AT (1) ATE186209T1 (no)
AU (1) AU716896B2 (no)
CZ (1) CZ289143B6 (no)
DE (2) DE19541260A1 (no)
ES (1) ES2141534T3 (no)
GR (1) GR3032523T3 (no)
IL (1) IL124279A (no)
MX (1) MX9803563A (no)
MY (1) MY132407A (no)
NO (1) NO982006L (no)
NZ (1) NZ318783A (no)
PL (1) PL326497A1 (no)
PT (1) PT859595E (no)
SK (1) SK281405B6 (no)
WO (1) WO1997017061A1 (no)
ZA (1) ZA969271B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
AU8877401A (en) * 2000-09-08 2002-03-22 Alza Corp Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
US20020187169A1 (en) * 2001-05-11 2002-12-12 Shoujun Chen Kavalactone compositions
EP1651197A1 (en) * 2003-07-28 2006-05-03 ALZA Corporation Transdermal warfarin-containing delivery system
WO2005094814A1 (ja) * 2004-03-31 2005-10-13 Kowa Co., Ltd. 外用剤
ES2385752T3 (es) 2006-04-26 2012-07-31 Rosemont Pharmaceuticals Ltd Composiciones orales líquidas
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7652767B2 (en) * 2006-10-19 2010-01-26 Sporian Microsystems, Inc. Optical sensor with chemically reactive surface
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
CN101652377A (zh) 2007-04-02 2010-02-17 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
DK2187742T3 (en) 2007-08-23 2018-01-08 Theracos Sub Llc (2S, 3R, 4R, 5S, 6R) -2- (4-CHLOR-3-BENZYLPHENYL) -6- (HYDROXYMETHYL) TETRAHYDRO-2H-PYRANE-3,4,5-TRIOLE DERIVATIVES FOR USING DIABETES
MX2011000637A (es) 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
CN105237502A (zh) 2008-08-22 2016-01-13 泰拉科斯萨伯有限责任公司 制备sglt2抑制剂的方法
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
EP2445506B1 (en) 2009-06-24 2014-12-31 Entarco SA The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US9420820B2 (en) 2013-08-09 2016-08-23 University Of Tsukuba Method for isolating polyphenols from olive mill water
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
WO2018184019A1 (en) 2017-03-31 2018-10-04 Curza Global, Llc Compositions and methods comprising substituted 2-aminoimidazoles
KR20210057053A (ko) 2018-08-23 2021-05-20 씨젠 인크. 항-tigit 항체
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
BR112023020662A2 (pt) 2021-04-09 2024-02-06 Seagen Inc Métodos de tratamento de câncer com anticorpos anti-tigit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
AU7547891A (en) * 1990-03-30 1991-10-30 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
NZ318783A (en) 1999-04-29
PL326497A1 (en) 1998-09-28
ATE186209T1 (de) 1999-11-15
AU716896B2 (en) 2000-03-09
CZ136698A3 (cs) 1998-07-15
KR100445940B1 (ko) 2005-09-30
KR19990067320A (ko) 1999-08-16
MX9803563A (es) 1998-09-30
PT859595E (pt) 2000-04-28
WO1997017061A1 (de) 1997-05-15
NO982006D0 (no) 1998-05-04
JP2001507331A (ja) 2001-06-05
DE59603597D1 (de) 1999-12-09
CZ289143B6 (cs) 2001-11-14
AU7085996A (en) 1997-05-29
MY132407A (en) 2007-10-31
EP0859595A1 (de) 1998-08-26
SK55898A3 (en) 1998-11-04
EP0859595B1 (de) 1999-11-03
SK281405B6 (sk) 2001-03-12
ES2141534T3 (es) 2000-03-16
IL124279A (en) 2003-07-06
DE19541260A1 (de) 1997-05-07
US6379696B1 (en) 2002-04-30
GR3032523T3 (en) 2000-05-31
CN1201385A (zh) 1998-12-09
ZA969271B (en) 1997-06-03

Similar Documents

Publication Publication Date Title
NO982006L (no) Terapeutisk preparat for transdermal tilf°rsel av virksomme stoffer gjennom huden
AU3984597A (en) Formulation of 5-ht agonists
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
WO2001027119A3 (de) Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine
YU59098A (sh) Derivati spiro-piperidina, postupak njihovog dobijanja, njihova upotreba u proizvodnji leka korisnog za lečenje ili prevenciju bolova, upalnih procesa, migrene, povraćanja i postherpetične neuralgije i farmaceutski sastav koji ih sadrži
WO1996019458A3 (en) Steroid receptor modulator compounds and methods
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AU3508497A (en) Androgen receptor modulator compounds and methods
AU2002342765A1 (en) Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations
HK1068103A1 (en) Selective androgen receptor modulators (sarms) for treating benign prostate hyperplasia
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
PT855916E (pt) Composicao farmaceutica contendo um estimulador de activina ou inibina
MX9601149A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.
DE69626544D1 (de) Arzneistoffe
WO2002055022A3 (en) Active metabolite of antifungal compound
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application